DESCRIPTION
Wednesday, January 14 | 1:00 - 2:00 pm (PT) | Zoom
BCLT Life Sciences Law & Policy Center
1.00 General CLE Credit Available
Program Information | Resources
As state psychedelic decriminalization efforts emerge and therapies using drugs like MDMA, psilocybin, and LSD advance through the FDA research and approval pipeline, broader access to psychedelic-assisted therapies (PATs) may soon be on the horizon. Yet, experts predict these therapies will be quite expensive, meaning the economic and logistical framework for delivering these novel treatments remains a significant challenge.
This panel will explore how psychedelic advocates, drug developers, private insurers, government programs, and individual patients will share the financial burden, and what models might work best to create equitable access for these therapies. Attendees will gain insight into the financial levers and regulatory changes required to make psychedelic medicine accessible for everyone.
Moderator
Vincent Joralemon, Life Sciences Law & Policy Center, BCLT, UC Berkeley Law
Speakers
Elliot Marseille, UC Berkeley
Sherry Rais, Enthea
Chris Raine, The Psychedelic Consultancy (Australia)
Dara Menashi, Psychedelic Mental Health Access Alliance